Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepotidacin Cardiac Conduction Study
NCT02257398Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gepotidacin in respiratory tract infection (RTI) (4 arms), sponsored by GSK. Primary endpoint: Change from baseline in corrected QT interval using Fridericia formula up to 48 hours. Started Oct 2014; status: completed.
02
Drugs
gepotidacin
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT02257398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257398.